Systemic side effects of glaucoma medications

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
   PubMed Web of Science ®Google Scholar
• Khazaeni B, Khazaeni L. Acute closed angle glaucoma. In: StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Walimbe T, Chelerkar V, Bhagat P, et al. Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol. 2016;10:821–827.
   Web of Science ®Google Scholar
• Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42–62.
   PubMed Web of Science ®Google Scholar
• Vaajanen A, Vapaatalo H. A single drop in the eye - effects on the whole body? Open Ophthalmol J. 2017;11:305–314.
   PubMed Web of Science ®Google Scholar
• Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433–2441.
   PubMed Web of Science ®Google Scholar
• Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc. 2008;106:138–145. discussion 145-138.
   PubMedGoogle Scholar
• Ellis PP, Wu PY, Pfoff DS, et al. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye. J Pharm Sci. 1992;81(3):219–220.
   Web of Science ®Google Scholar
• Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. Am J Ophthalmol. 1989;107(2):151–155.
   Web of Science ®Google Scholar
• Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3(1):53–72.
   PubMedGoogle Scholar
• Schmidl D, Schmetterer L, Garhofer G, et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77.
   PubMed Web of Science ®Google Scholar
• Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012;27(12):4273–4287.
   Web of Science ®Google Scholar
• Aslam S, Gupta V. Carbonic anhydrase inhibitors. In: StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Kerber JM, de Mello JD, Moura KBA, et al. Acetazolamide intoxication in an elderly patient with diabetes and chronic renal failure after cataract surgery. Case Rep Crit Care. 2020;2020:3764972.
   Google Scholar
• Zaidi FH, Kinnear PE. Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes. Br J Ophthalmol. 2004;88(5):714–715.
   Web of Science ®Google Scholar
• Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977;95(8):1378–1382.
   Google Scholar
• Lichter PR, Newman LP, Wheeler NC, et al. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978;85(4):495–502.
   PubMed Web of Science ®Google Scholar
• Committee NIIHSGW, Wall M, McDermott MP, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014;311(16):1641–1651.
   Web of Science ®Google Scholar
• Carbonic anhydrase inhibitors. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD); 2012.
   Google Scholar
• Fraunfelder FT, Meyer SM, Bagby GC Jr., et al. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985;100(1):79–81.
   Web of Science ®Google Scholar
• Jachiet M, Bellon N, Assier H, et al. Cutaneous adverse drug reaction to oral acetazolamide and skin tests. Dermatology. 2013;226(4):347–352.
   Web of Science ®Google Scholar
• Kelly TE, Hackett PH. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol. 2010;11(4):319–323.
   Web of Science ®Google Scholar
• Thien T. Br effects aam RL, Russel FG. [Fatal anaphylactic reaction after oral acetazolamide (diamox) for glaucoma]. Ned Tijdschr Geneeskd. 2000;144(45):2173–2174.
   Google Scholar
• Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879–884.
   PubMed Web of Science ®Google Scholar
• Vogiatzis I, Koulouris E, Sidiropoulos A, et al. Acute pulmonary edema after a single oral dose of acetazolamide. Hippokratia. 2013;17(2):177–179.
   Web of Science ®Google Scholar
• Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42(2):137–151.
   PubMed Web of Science ®Google Scholar
• Kluger N, Guillot B, Raison-Peyron N. Systemic contact dermatitis to dorzolamide eye drops. Contact Dermatitis. 2008;58(3):167–168.
   Web of Science ®Google Scholar
• Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol. 1999;117(8):1087–1088.
   Google Scholar
• thoe Schwartzenberg GW, Trope GE. Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt). Can J Ophthalmol. 1999;34(2):93–94.
   Web of Science ®Google Scholar
• Lewis PR, Phillips TG, Sassani JW. Topical therapies for glaucoma: what family physicians need to know. Am Fam Physician. 1999;59(7):1871–1879, 1882.
   Web of Science ®Google Scholar
• Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol. 2002;283(2):R287–295.
   Web of Science ®Google Scholar
• Buerkle H, Yaksh TL. Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth. 1998;81(2):208–215.
   Web of Science ®Google Scholar
• Giovannitti JA Jr., Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31–39.
   PubMedGoogle Scholar
• Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6(3):254–285.
   PubMed Web of Science ®Google Scholar
• Kampik A, Arias-Puente A, O’Brart DP, et al. European Latanoprost Study G. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002;11(2):90–96.
   PubMed Web of Science ®Google Scholar
• Yuksel N, Karabas L, Altintas O, et al. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. Ophthalmologica. 2002;216(1):45–49.
   Web of Science ®Google Scholar
• Sodhi PK, Verma L, Ratan J. Dermatological side effects of brimonidine: a report of three cases. J Dermatol. 2003;30(9):697–700.
   Web of Science ®Google Scholar
• Robin AL, Coleman AL. Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate. Trans Am Ophthalmol Soc. 1990;88:149–159. discussion 159-162.
   Google Scholar
• Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79(12):1098–1101.
   PubMed Web of Science ®Google Scholar
• Holmwood PC, Chase RD, Krupin T, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol. 1992;114(1):19–22.
   Web of Science ®Google Scholar
• Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med. 1990;112(2):120–125.
   Web of Science ®Google Scholar
• Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol. 1978;85(4):447–453.
   PubMed Web of Science ®Google Scholar
• Little JW. Thyroid disorders. Part I: hyperthyroidism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):276–284.
   Web of Science ®Google Scholar
• Kerr CR, Hass I, Drance SM, et al. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. Br J Ophthalmol. 1982;66(2):109–114.
   Web of Science ®Google Scholar
• Patel NM, Dewaswala N. Parasympathomimetic medications. In: StatPearls. Treasure Island (FL); 2020.
   Google Scholar
• Pakala RS, Brown KN, Preuss CV. Cholinergic medications. In: StatPearls. Treasure Island (FL); 2020.
   Google Scholar
• Littmann L, Kempler P, Rohla M, et al. Severe symptomatic atrioventricular block induced by pilocarpine eye drops. Arch Intern Med. 1987;147(3):586–587.
   Google Scholar
• Reyes PF, Dwyer BA, Schwartzman RJ, et al. Mental status changes induced by eye drops in dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1987;50(1):113–115.
   Web of Science ®Google Scholar
• Arens AM, Kearney T. Adverse Effects of Physostigmine. J Med Toxicol. 2019;15(3):184–191.
   PubMed Web of Science ®Google Scholar
• Becker B, Gage T. Demecarium bromide and echothiophate iodide in chronic glaucoma. Arch Ophthalmol. 1960;63:102–107.
   Google Scholar
• Pratt-Johnson JA, Drance SM, Innes R. Comparison between pilocarpine and echothiophate for chronic simple glaucoma. A comparison between 4 per cent pilocarpine and 0.06 per cent echothiophate iodine in the diurnal management of chronic simple glaucoma. Arch Ophthalmol. 1964;72:485–488.
   PubMedGoogle Scholar
• Shim MS, Kim KY, Ju WK. Role of cyclic AMP in the eye with glaucoma. BMB Reports. 2017;50(2):60–70.
   Web of Science ®Google Scholar
• Tucker WD, Sankar P, Theetha Kariyanna P. Selective beta-1-blockers. In: StatPearls. Treasure Island (FL); 2020.
   Google Scholar
• Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322.
   PubMed Web of Science ®Google Scholar
• Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28:Suppl:55–63.
   Web of Science ®Google Scholar
• Martin-Timon I, Del Canizo-Gomez FJ. Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes. 2015;6(7):912–926.
   PubMed Web of Science ®Google Scholar
• Mitidieri E, Tramontano T, Gurgone D, et al. beta3 adrenergic receptor activation relaxes human corpus cavernosum and penile artery through a hydrogen sulfide/cGMP-dependent mechanism. Pharmacol Res. 2017;124:100–104.
   Web of Science ®Google Scholar
• Kristensen BO, Steiness E, Weeke J. Propranolol withdrawal and thyroid hormones in patients with essential hypertension. Clin Pharmacol Ther. 1978;23(6):624–629.
   Web of Science ®Google Scholar
• Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990;40(1):75–90.
   PubMed Web of Science ®Google Scholar
• Erkin EF, Celik P, Kayikcioglu O, et al. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica. 2006;220(5):332–337.
   Web of Science ®Google Scholar
• Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986;104(2):197–199.
   Web of Science ®Google Scholar
• Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986;102(5):606–611.
   PubMed Web of Science ®Google Scholar
• Coppeto JR. Transient ischemic attacks and amaurosis fugax from timolol. Ann Ophthalmol. 1985;17(1):64–65.
   Google Scholar
• Verkijk A. Worsening of myasthenia gravis with timolol maleate eyedrops. Ann Neurol. 1985;17(2):211–212.
   Web of Science ®Google Scholar
• Maenpaa J, Volotinen-Maja M, Kautiainen H, et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops. Drug Metab Dispos. 2014;42(12):2068–2076.
   Web of Science ®Google Scholar
• Wang Z, Denys I, Chen F, et al. Complete atrioventricular block due to timolol eye drops: a case report and literature review. BMC Pharmacol Toxicol. 2019;20(1):73.
   PubMed Web of Science ®Google Scholar
• Walia HS, Walia SS, Emanuel ME. Sick sinus syndrome associated with topical timolol maleate instillation. J Pharmacol Pharmacother. 2011;2(4):300–302.
   Google Scholar
• Chrisp P, Sorkin EM. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1992;2(1):58–77.
   Web of Science ®Google Scholar
• Mirza GE, Karakucuk S, Temel E. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma. 2000;9(1):45–50.
   Web of Science ®Google Scholar
• Yamamoto T, Kitazawa Y, Noma A, et al. The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma. 1996;5(4):252–257.
   Web of Science ®Google Scholar
• Yu Y, Lucitt MB, Stubbe J, et al. Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci U S A. 2009;106(19):7985–7990.
   Web of Science ®Google Scholar
• Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998;32(4):504–505.
   PubMed Web of Science ®Google Scholar
• Lee K, Lee SH, Kim TH. The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy. Int J Mol Sci. 2020;21:5.
   Web of Science ®Google Scholar
• Ohyama K, Sugiura M. Evaluation of the association between topical prostaglandin F2alpha analogs and asthma using the JADER database: comparison with beta-blockers. Yakugaku Zasshi. 2018;138(4):559–564.
   Web of Science ®Google Scholar
• Chen R, Yang K, Zheng Z, et al. Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma. J Glaucoma. 2016;25(3):e134–144.
   PubMed Web of Science ®Google Scholar
• Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50(5):956–962.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45(5):1360–1368.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol. 2011;26(4–5):285–289.
   PubMed Web of Science ®Google Scholar
• Hollo G, Aung T, Cantor LB, et al. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: mechanism, diagnosis, and management. Surv Ophthalmol. 2020;65(5):496–512.
   PubMed Web of Science ®Google Scholar
• Tenny S, Patel R, Thorell W. Mannitol. In: StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Domaingue CM, Nye DH. Hypotensive effect of mannitol administered rapidly. Anaesth Intensive Care. 1985;13(2):134–136.
   Web of Science ®Google Scholar
• Tsai SF, Shu KH. Mannitol-induced acute renal failure. Clin Nephrol. 2010;74(1):70–73.
   Web of Science ®Google Scholar
• Spaeth GL, Spaeth EB, Spaeth PG, et al. Anaphylactic reaction to mannitol. Arch Ophthalmol. 1967;78(5):583–584.
   Google Scholar
• Park J, Kwak Y, Kim CH, et al. Intraoperative mannitol administration increases the risk of postoperative chronic subdural hemorrhage after unruptured aneurysm surgery. World Neurosurg. 2019;127:e919–e924.
   Web of Science ®Google Scholar
• Murray D. Emergency management: angle-closure glaucoma. Community Eye Health. 2018;31(103):64.
   Google Scholar
• Dasso L, Al-Khaled T, Sonty S, et al. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018;12:1939–1944.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127.
   PubMed Web of Science ®Google Scholar
• Clinical review report: latanoprostene bunod (vyzulta): (Bausch Health, Canada Inc.): indication: for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Ottawa (ON); 2019.
   Google Scholar
• Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther. 2008;10(Suppl 2):S3.
   Google Scholar
• Chen K, Popel AS. Nitric oxide production pathways in erythrocytes and plasma. Biorheology. 2009;46(2):107–119.
   Web of Science ®Google Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965–973.
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR. Glaucoma medications in pregnancy. Oman J Ophthalmol. 2018;11(3):195–199.
   Google Scholar
• Coppens G, Stalmans I, Zeyen T. Glaucoma medication during pregnancy and nursing. Bull Soc Belge Ophtalmol. 2010;314:33–36.
   PubMedGoogle Scholar
• Worsham F Jr., Beckman EN, Mitchell EH. Sacrococcygeal teratoma in a neonate. Association with maternal use of acetazolamide. JAMA. 1978;240(3):251–252.
   Web of Science ®Google Scholar
• Al-Saleem AI, Al-Jobair AM. Possible association between acetazolamide administration during pregnancy and multiple congenital malformations. Drug Des Devel Ther. 2016;10:1471–1476.
   PubMed Web of Science ®Google Scholar
• Ozawa H, Azuma E, Shindo K, et al. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr. 2001;160(5):321–322.
   Web of Science ®Google Scholar
• Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45(5):449–454.
   PubMed Web of Science ®Google Scholar
• Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. Am J Ophthalmol. 1988;106(5):616–623.
   PubMed Web of Science ®Google Scholar
• Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol. 2014;25(2):93–97.
   PubMed Web of Science ®Google Scholar
• De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol. 2004;138(2):305–306.
   PubMed Web of Science ®Google Scholar
• Wagenvoort AM, van Vugt JM, Sobotka M, et al. Topical timolol therapy in pregnancy: is it safe for the fetus? Teratology. 1998;58(6):258–262.
   Google Scholar
• Mendez-Hernandez C, Garcia-Feijoo J, Saenz-Frances F, et al. Topical intraocular pressure therapy effects on pregnancy. Clin Ophthalmol. 2012;6:1629–1632.
   PubMedGoogle Scholar
• Ho JD, Hu CC, Lin HC. Antiglaucoma medications during pregnancy and the risk of low birth weight: a population-based study. Br J Ophthalmol. 2009;93(10):1283–1286.
   Web of Science ®Google Scholar
• Coleman AL, Mosaed S, Kamal D. Medical therapy in pregnancy. J Glaucoma. 2005;14(5):414–416.
   Web of Science ®Google Scholar
• Seyberth HW, Kauffman RE. Basics and dynamics of neonatal and pediatric pharmacology. Handb Exp Pharmacol. 2011;205:3–49.
   Google Scholar
• Rodieux F, Wilbaux M, van den Anker JN, et al. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54(12):1183–1204.
   PubMed Web of Science ®Google Scholar
• Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet. 2002;41(13):1077–1094.
   PubMed Web of Science ®Google Scholar
• Lustgarten JS, Podos SM. Topical timolol and the nursing mother. Arch Ophthalmol. 1983;101(9):1381–1382.
   Google Scholar
• Johnsson G, Regardh CG. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet. 1976;1(4):233–263.
   PubMedGoogle Scholar
• Belkin A, Chen T, DeOliveria AR, et al. A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma. 2020;3(2):79–89.
   Google Scholar
• Samant M, Medsinge A, Nischal KK. Pediatric glaucoma: pharmacotherapeutic Options. Paediatr Drugs. 2016;18(3):209–219.
   Web of Science ®Google Scholar
• Prok L, Hall D. A 24-day old with episodic lethargy, hypotonia, and apnea: the eyes have it. Curr Opin Pediatr. 2003;15(2):226–228.
   Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5(5):281–284.
   PubMed Web of Science ®Google Scholar
• Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye (Lond). 2004;18(1):24–26.
   PubMed Web of Science ®Google Scholar
• Wright TM, Freedman SF. Exposure to topical apraclonidine in children with glaucoma. J Glaucoma. 2009;18(5):395–398.
   PubMed Web of Science ®Google Scholar
• Boger WP 3rd, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology. 1981;88(3):253–258.
   Web of Science ®Google Scholar
• Olson RJ, Bromberg BB, Zimmerman TJ. Apneic spells associated with timolol therapy in a neonate. Am J Ophthalmol. 1979;88(1):120–122.
   PubMed Web of Science ®Google Scholar
• Maris PJ Jr., Mandal AK, Netland PA. Medical therapy of pediatric glaucoma and glaucoma in pregnancy. Ophthalmol Clin North Am. 2005;18(3):461–468, vii.
   Google Scholar
• Morris S, Geh V, Nischal KK, et al. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol. 2003;87(8):1052–1053.
   Web of Science ®Google Scholar
• Ott EZ, Mills MD, Arango S, et al. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol. 2005;123(9):1177–1186.
   Google Scholar
• Ebied AM, Gracey S. Acetazolamide-induced sickle cell crisis. Ann Pharmacother. 2018;52(10):1047–1048.
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002;47(Suppl 1):S129–132.
   PubMedGoogle Scholar
• Raber S, Courtney R, Maeda-Chubachi T, et al. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Ophthalmology. 2011;118(10):2022–2027.
   PubMed Web of Science ®Google Scholar
• Schmidtborn F. [Systemic side-effects of latanoprost in a child with aniridia and glaucoma]. Ophthalmologe. 1998;95(9):633–634.
   Web of Science ®Google Scholar
• Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs. 2007;9(2):71–79.
   PubMedGoogle Scholar